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Inflammation is a central component of progressive chronic
kidney disease (CKD). Iron promotes oxidative stress and
inflammatory response in animals and promotes progressive
CKD. Parenteral iron provokes oxidative stress in patients
with CKD; however, its potential to provoke an inflammatory
response is unknown. In 20 veterans with CKD, 100 mg iron
sucrose was administered intravenously over 5 min and
urinary excretion rate and plasma concentration of monocyte
chemoattractant protein-1 (MCP-1) were measured at timed
intervals over 24 h. Patients were then randomized to
placebo or N-acetyl cysteine (NAC) 600 mg b.i.d. and the
experiment was repeated at 1 week. Iron sucrose markedly
increased plasma concentration and urinary excretion rate of
MCP-1 at baseline and at 1 week visits (Po0.0001 for time
effect). Urinary excretion peaked at 30 min and plasma
concentration at 15 min. Plasma MCP-1 concentration fell
from 164717.7 to 135717.7 pg/ml with NAC, whereas it
remained unchanged from 133712.5 to 132717.7 pg/ml
with placebo (P¼ 0.001 for visit antioxidant drug
interaction). There was a reduction in MCP-1 urinary
excretion rate from visit 1 to 2. At the baseline visit, the
urinary excretion rate averaged 305766 pg/min and at
the second visit 245767 pg/min (mean difference
60728 pg/min, P¼ 0.030). There was no improvement in
urinary MCP-1 excretion with NAC. In conclusion, iron sucrose
causes rapid and transient generation and/or release of
MCP-1 plasma concentration and increases urinary excretion
rate, and systemic MCP-1 level but the urinary excretion
rate is not abrogated with the antioxidant NAC. These results
may have implications for the progression of CKD with
parenteral iron.
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Inflammation plays a central role in the progression of
chronic kidney disease (CKD).1 Iron produces glomerular2
and tubular injury, and3–5 is associated with the accelerated
progression of CKD.6 Removal of dietary iron abrogates the
progression of kidney disease.7 However, iron is often needed
in the management of anemia in patients with CKD and,
recently, the US Food and Drug Administration approved the
use of iron sucrose for the treatment of iron deficiency
anemia in patients with CKD.
Monocyte chemoattractant protein-1 (MCP-1) is a pro-
inflammatory chemokine,8 which also has profibrotic9 and
procoagulant effects.10 In addition, MCP-1 causes endothelial
activation11 and may cause direct tissue injury.12 Urinary
excretion of MCP-1 correlates with the extent of renal
inflammation13 as well as MCP-1 gene expression in the
tubules, parietal epithelial cells, and infiltrating monocytes.14
The MCP-1 gene expression is redox-sensitive15 and, at least
in part, regulated by nuclear factor-kB activation. Intra-
venous (i.v.) iron produces a marked pro-oxidant effect.16,17
In keeping with these pro-oxidant effects of i.v. iron, data
from Zager18 demonstrate a rapid onset of MCP-1 accumu-
lation in plasma, kidney, and other organs with i.v. iron
administration. These deleterious effects of i.v. iron are parti-
cularly relevant to CKD because a single i.v. injection of iron
dextran increases oxidative stress in the cardiovascular tissues
in animals with CKD, but not in those without CKD.19
Based on these animal experiments, it was hypothesized
that in patients with CKD administered i.v. iron, MCP-1
plasma concentration and urinary excretion rate will increase.
The purpose of this report is to describe the time course of
MCP-1 accumulation in plasma and urinary excretion, and to
assess the anti-inflammatory response to the antioxidant
N-acetyl cysteine (NAC).
RESULTS
Assay performance
The standard curve had excellent curve fit with r2 of 40.999
in all instances. The mean plasma MCP-1 level of eight
plasma samples was 279.2 pg/ml. The interassay coefficient of
variation (CV) was 7.4%. Furthermore, 90.3% of the variance
in MCP-1 plasma level was attributable to difference between
samples and only 9.7% to differences between days. The
intraday CVs for each of the 6 days for plasma samples were
2.8, 6.9, 5.4, 4.7, 7.1, and 4.7%.
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The mean urinary MCP-1 level of eight urine samples was
241.3 pg/ml. The interassay CV was 11.2%. A total of 98.8%
of the variance in MCP-1 plasma level was attributable to
differences between samples and 1.2% to differences between
days. The intraday CVs for each of the 6 days for plasma
samples were 3.4, 4.8, 2.1, 2.0, 12.1, and 3.5%.
Trial results
Changes in plasma MCP-1 concentration. Three effects were
tested in this analysis: group assignment (NAC vs placebo),
visit (first exposure vs second exposure), and time effect and
the two- and three-way interactions. The overall results
are shown in Table 1. There was no group difference in the
visit 1 concentration of plasma MCP-1 between the NAC
group (164 pg/ml, standard error of mean (s.e.m.) 17.7) and
placebo group (140 pg/ml, s.e.m. 17.7). There was a highly
significant time-dependent change in plasma MCP-1 con-
centration with i.v. iron injection (Po0.001 for time effect)
(Figure 1 and Table 1).
The second administration of i.v. iron was associated
with a reduction in MCP-1 level from 152712.5 to 1337
12.5 pg/ml, a reduction of 18.573.3 (Po0.001), and was
associated with a later peaking of MCP-1 (visit effect
Po0.001) (Table 2).
There was a significant increase in plasma MCP-1
concentration with the second i.v. iron injection after 1 week.
Furthermore, the MCP-1 concentration in the NAC group was
lower. In the NAC group, plasma MCP-1 concentration fell
from 164717.7 to 135717.7 pg/ml (Figure 1), whereas it
remained unchanged from 133712.5 to 132717.7 pg/ml with
placebo (P¼ 0.001 for visit antioxidant drug interaction).
There was a significant visit time interaction (Po0.0001).
This is shown in Table 2. Whereas there was an early peak and
rapid reduction at baseline visit, there was a lower peak and a
more sustained response at week 1.
Changes in urinary MCP-1 excretion rate. There were no
differences in urinary MCP-1 excretion rate between the NAC
group and placebo group. The overall concentration was
280789 pg/min in the NAC group and 271795 pg/min in
the placebo group at baseline (P¼NS for difference). There
was a time-dependent increase in urinary excretion of MCP-1
in response to i.v. iron sucrose (Po0.001; Figure 1) that
Table 1 | Plasma MCP-1 concentration and urine excretion rate profile in patients given placebo or NAC
Plasma MCP-1 concentration
Placebo group NAC group
Time (min) Baseline MCP-1 (pg/ml) Week 1 MCP-1 (pg/ml) Baseline MCP-1 (pg/ml) Week 1 MCP-1 (pg/ml)
0 133.9719.2 113.6719.2 182.9719.2 128.9719.3
15 160.5720.2 135.9720.7 200.6719.8 152.3719.8
30 160.1719.5 143.7719.2 162.9719.5 144.1719.5
60 142.4719.0 156.8719.2 162.5719.0 136.1719.0
120 138.6719.0 153.6719.2 137.7719.0 143.5718.9
180 124.9720.2 123.2719.8 161.4719.7 135.9719.2
1440 119.4719.8 98.0719.8 140.6719.0 103.6719.4
Urine MCP-1 excretion rate
Placebo group NAC group
Time (min) Baseline MCP-1 (pg/min) Week 1 MCP-1 (pg/min) Baseline MCP-1 (pg/min) Week 1 MCP-1 (pg/min)
0 2437135.2 214.87155.3 281.37124 236.87124
15 279.47114.8 269.67114.9 373.87106.5 2347108.6
30 386.67122 509.57135.1 599.67106.5 404.77108.6
60 291.67112.3 227.27118 280.57106.5 156.17106.5
120 1847112.3 1707118 178.97108.6 153.47111.2
180 291.77114.8 189.47114.9 321.27111.2 102.17111.2
1440 278.57112.3 259.87118 257.17111.2 322.87106.5
MCP-1: monocyte chemoattractant protein-1; NAC: N-acetyl cysteine.
240
220
200
180
160
140
120
100
80
0 30 60 90 120 150 180 1440
0
0
30 60 90 120 150 180 1440
Time (min)
Time (min)
Pre-NAC
Post-NAC
Pre-NAC
Post-NAC
750
600
450
150
300
Ur
in
ar
y 
ex
cr
e
tio
n 
ra
te
o
f M
CP
-1
 (p
g/m
in)
Pl
as
m
a 
M
CP
-1
 (p
g/m
l)
Figure 1 | Time course of plasma MCP-1 concentration and urinary
MCP-1 excretion rate following i.v. iron sucrose injection before and
after administration of the antioxidant NAC. There was a significant
increase in plasma concentration and urinary excretion rate of
MCP-1 in response to i.v. iron sucrose. NAC decreased plasma
MCP-1 concentration but not the urinary excretion rate of MCP-1
(see Results for details).
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peaked at the 30 min urine collection. There was a reduction
in MCP-1 urinary excretion rate from visit 1 to visit 2. At
the baseline visit, the urinary excretion rate averaged to
305766 pg/min, and at the second visit it averaged to
245767 pg/min (mean difference 60728 pg/min, P¼ 0.030).
However, there was no statistically significant improve-
ment in MCP-1 urinary excretion rate in response to NAC
administration. In the NAC group, mean MCP-1 excretion
rate was 330791 pg/min at baseline and 230791 pg/min at
one week. In the placebo group, MCP-1 excretion rate was
281796 pg/min at baseline and 260798 pg/min at 1 week
(P¼ 0.147 for visit antioxidant drug interaction). There
was no visit time interaction.
DISCUSSION
Major findings
The rapid increase in MCP-1 with a single dose of i.v. iron in
the recommended doses in patients with CKD suggests that
i.v. iron has the potential to generate not only oxidative
stress, but also an inflammatory response. MCP-1 urinary
excretion peaked at 30 min, similar to the peak seen with
oxidative stress and proteinuric responses that we have
reported earlier.20 This suggests that oxidative stress,
proteinuria, and inflammation may share common patho-
physiological pathways. The urinary excretion rates of MCP-1
were more impressive than the plasma concentration-time
changes, possibly because the urinary excretion rate may
represent the composite of filtration of circulating MCP-1 as
well as the intrarenal generation and release of MCP-1.
The reduction in plasma MCP-1 concentration with NAC
suggests that antioxidants have the potential to reduce the
systemic inflammatory response associated with i.v. iron
administration. However, we did not see any reduction in
proteinuria, enzymuria, or MCP-1 urinary excretion rate with
antioxidant therapy, which suggests that mechanisms inde-
pendent of oxidative stress may be mediating the renal injury
response. Furthermore, the systemic response as evidenced by
the abrogation of plasma MCP-1 response may be more
redox-sensitive compared to urinary MCP-1 excretion.
Biological plausibility
The results of this study are consistent with the observations
of Zager18 in animals. Zager injected 2 mg of iron gluconate
i.v. in CD-1 mice and found three-fold elevation of plasma
MCP-1 at 3 h and about two-fold elevation of MCP-1 level
at 24 h. Similar time course of MCP-1 protein elevation was
observed in the renal cortex. Iron dextran did not increase
plasma MCP-1; iron gluconate caused a larger increase in
plasma MCP-1 concentration compared to iron sucrose.
The greatest elevation in mRNA for MCP-1 was not
observed in the kidney but in the liver after systemic adminis-
tration of iron sucrose, but not with iron dextran. In the
kidney, iron dextran did not increase mRNA for MCP-1; iron
gluconate caused a larger increase in mRNA for MCP-1 than
iron sucrose. In an obstructive uropathy model, kidney
MCP-1 level was higher in the obstructed compared to
unobstructed kidney. The level of elevation of MCP-1 protein
was compounded by iron gluconate. In fact, iron gluconate
stimulated MCP-1 production even in HK2 cells, a human
proximal tubular cell line.
These animal data increase our understanding of the
observations made in patients with CKD and lend biological
plausibility to the results. However, the rapid and early
increase in plasma and urinary MCP-1 excretion rate suggests
that preformed MCP-1 may be released rapidly in response to
i.v. iron.
Limitations
There are some limitations to our study. The analyses of
samples in blood and urine were performed post hoc and
were not part of the original trial design. As the samples
were stored at 801C, it is unlikely that the samples were
degraded. Even if some degradation was to occur over 18
months of storage, the repeated measures design would allow
comparison of each subject against himself and avoid biasing
the results. Owing to the small size of the study, subgroup
analyses were not performed, as they are not meaningful. We
also did not compare different iron preparations, which likely
have different toxicological profiles.2,21
Clinical implications
These data demonstrate, for the first time in humans, that i.v.
iron can rapidly generate an inflammatory response. The
clinical implications of the generation of an inflammatory
response are speculative. One possible interpretation of these
data is that as the stimulation of MCP-1 is transient, it is of
little consequence. However, caution is warranted with this
interpretation. Repeated i.v. iron exposure may not produce
just transient, inconsequential injury. Nath et al.22 have
demonstrated that repetitive exposure of kidney to nephro-
toxic heme proteins leads to chronic tubulointerstitial
disease, which in part is due to chronic upregulation of
oxidant inducible genes such as MCP-1. That repetitive acute
renal injury may lead to CKD is exemplified by acute cellular
rejection followed by chronic allograft nephropathy and
repeated acute obstruction followed by chronic renal failure.
Even if such injury is mild, it can lead to the generation of
sodium-sensitive hypertension.23 Whether the inflammatory
response generated by repeated i.v. iron administration exacts
Table 2 | Plasma MCP-1 concentration at baseline and after
second i.v. iron injection
Time (min) Baseline MCP-1 (pg/ml) Week 1 MCP-1 (pg/ml)
0 158714 121714
15 181714 144714
30 161714 144714
60 152713 146714
120 138713 149713
180 143714 129714
1440 130714 101714
The pattern of MCP-1 plasma concentration was different on repeat administration.
An early peak and rapid reduction was seen at baseline, but a lower peak and more
sustained response was seen after repeat injection. Values are mean7s.e.m. MCP-1:
monocyte chemoattractant protein-1.
Kidney International (2006) 69, 1259–1263 1261
R Agarwal: Iron sucrose MCP-1 and CKD o r i g i n a l a r t i c l e
a long-term cost with progressive tubulointerstitial disease or
declining glomerular filtration rate is unknown.
Zager et al. have shown in animal models that i.v. iron
can compound the inflammatory response associated with
endotoxemia24 and rhabdomyolysis.25 As an excess inflam-
matory response is central to adverse outcomes in sepsis, it is
likely that i.v. iron may similarly compound the inflamma-
tory state associated with sepsis in humans. Accordingly,
caution is warranted when using these drugs in patients with
bacteremia or sepsis.
Finally, patient factors that dictate inflammation may
afford susceptibility to long-term decline in glomerular filtra-
tion rate when exposed to i.v. iron. For example, patients
demonstrating a greater area under the curve of MCP-1
plasma concentration time curve or those harboring unfavor-
able genotypes may have a greater predisposition to a
decline in kidney function in the long term when exposed to
i.v. iron.26 These hypotheses would need to be tested in
prospective randomized trials.
MATERIALS AND METHODS
Subjects
The study design and primary results of the study have been
previously published.20 Briefly, 20 veteran men of average (s.d.) age
73 (7) years, weight 96 (21.3) kg, and average estimated glomerular
filtration rate 26 (7.2) ml/min participated in the study after
regulatory approval and written informed consent. Twelve patients
had diabetes, six had hypertension, and two had uncertain causes of
CKD. All patients completed the study, except for one patient who
died 2 days after the first injection of i.v. iron sucrose of causes
unrelated to the i.v. iron or study procedures.
After baseline collection of blood and urine, subjects received an
i.v. dose of iron sucrose (Venofer, American Regent Laboratories
Inc., Shirley, NY, USA) at a dose of 100 mg infused over 5 min.
One hour before iron injection, subjects were asked to drink
water (10–15 ml/kg body weight) and the urinary losses were
replaced by additional water to encourage urine flow and frequent
urine sampling. Blood and urine collections were obtained at
0.25, 0.5, 1, 2, 3, and 24 h after iron dosing. Urine and plasma
were immediately frozen in aliquots and stored at 801C until
analysis. Subjects were assigned by a computer-generated permuted
block randomization scheme to one of two open-label, 1-week,
parallel treatment arms: either no active intervention or treatment
with the antioxidant NAC (Mucomyst, Apothecon Inc., Princeton,
NJ, USA) at a dose of 600 mg twice a day for 1 week. After 1 week,
subjects had all study procedures repeated as in the initial study
period. Thus, the groups of subjects who received no intervention
are reported as ‘pre-placebo’ and ‘post-placebo’ and the other
groups of subjects who received NAC are reported as ‘pre-NAC’ and
‘post-NAC’.
MCP-1 assay
A sandwich enzyme-linked immunoassay procedure was developed
using commercially available reagents. Enzyme-linked immunoassay
plates (Costar, 3590, Corning, NY, USA) were coated with 100 ml/
well capture monoclonal anti-human MCP-1 antibody (R&D
Systems, MAB 679, Minneapolis, MN, USA) 5mg/ml in phos-
phate-buffered saline (PBS). Plates were incubated overnight at
room temperature, covered with an adhesive strip. Using 0.05%
Tween 20 in PBS, plates were washed a total of three times with a
microplate washer (Skan Washer 400, Molecular Devices, Sunnyvale,
CA, USA). After the last wash, excess wash buffer was removed and
the plates were blocked for 1 h with 1% bovine serum albumin in
PBS. The plates were again washed a total of three times using the
above method. Samples of plasma or urine were assayed in duplicate
after 1:1 dilution in 1% bovine serum albumin in PBS. A 100ml
portion of standards or sample was added to the plate in duplicate
and the plate was incubated for 2 h at room temperature. A seven-
point MCP-1 standard curve was created in duplicate with two-fold
serial dilutions of 700 pg/ml standard (R&D systems). Tris-buffered
saline in 0.1% bovine serum albumin was used to reconstitute the
detection antibody (Biotinylated Anti-human MCP-1 Antibody
R&D BAF279) to a concentration of 50 mg/ml. A final concentration
of 100 ng/ml of detection antibody was obtained by diluting in 1%
bovine serum albumin in PBS. Detection was carried out by
incubating 100 ml/well of detection antibody for 2 h, washing three
times using the above technique, and using the streptavidin-
horseradish peroxidase system for color development. The plate
was subsequently read at 450 nm with subtraction of absorbance
at 540 nm using an enzyme-linked immunoassay plate reader
(Spectra Max 190, Molecular Devices, Sunnyvale, CA, USA).
Softmax Pro software (Molecular Devices, Sunnyvale, CA, USA)
was used to fit a four-parameter logistic curve fit to determine
MCP-1 concentrations in the sample. Repeatability of the assay was
assessed as noted below.
Statistical analysis
Interassay and intra-assay CV. To determine the interassay
variability, eight samples each of urine and plasma from eight
patients were assayed in duplicate on 6 separate days over a 2-week
period. For each assay, a standard curve was created in duplicate. A
variance component model was used to analyze the data separately
for urine and plasma. In this model, MCP-1 level was treated as the
dependent variable, sample ID as the random variable, and day of
analysis as the fixed variable. The main effect of sample and day
was tested. The assumption of this model is that the interaction
between days and samples is zero. A restricted maximum likelihood
estimation approach was used to calculate the components of
variance. The square root of the variance attributable to days was
divided by the overall mean MCP-1 level to yield the interday CV.
To calculate the intraday CV, sample ID was used as the random
variable and data were analyzed for each day separately for a specific
sample matrix – urine or plasma.
Analysis of trial results. Because urine and plasma levels of
MCP-1 were measured repeatedly in the same patient, a repeated
measures analysis of variance model was used to analyze the results.
In this model, MCP-1 plasma concentration or urinary excretion
rate was used as a dependent variable in separate models. Repeated
measures of time, visits (two visits separated by 1 week), and
antioxidant drug assignment (placebo or NAC) were tested along
with all the interaction terms (time visit, visit antioxidant drug,
visit antioxidant drug, time visit antioxidant drug). The
three-way interaction term was found to be not significant and it
was removed from the final model. Post hoc tests were Bonferroni
corrected and two-sided significance at Po0.05 was taken as
statistically significant. All analyses were performed using SPSS for
Windows (version 13.0, SPSS Inc., Chicago, IL, USA).
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